Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.
Loading...
Embargo End Date
ICR Authors
Authors
Shah, V
Boyd, KD
Houlston, RS
Kaiser, MF
Boyd, KD
Houlston, RS
Kaiser, MF
Document Type
Journal Article
Date
2017-11-06
Date Accepted
2017-10-30
Abstract
BACKGROUND: Multiple Myeloma is a cancer of plasma cells associated with significantly reduced survival. Long term survivorship from myeloma is very rare and despite advances in its treatment the disease is generally considered incurable. We report a patient diagnosed with myeloma carrying a germline mutation of a tumour suppressor gene who has effectively been cured. CASE PRESENTATION: A 36-year-old woman was diagnosed with IgG lambda myeloma in 1985. She was treated with melphalan chemotherapy followed by high-dose melphalan and autologous stem cell rescue and since remained in complete remission despite not having received any additional therapy. After eliciting a prior history of multiple primary melanomas and breast cancer, she was tested for and shown to be a carrier for a germline mutation in CDKN2A. CONCLUSIONS: This is the second case report of germline mutation of CDKN2A being associated with myeloma. CDKN2A is a stabiliser of p53. Long term survivorship after high dose DNA damaging chemotherapy with melphalan in this patient is compatible with an increased chemo-sensitivity due to impairment of the DNA repair pathway.
Citation
BMC cancer, 2017, 17 (1), pp. 718 - ?
Source Title
Publisher
BMC
ISSN
1471-2407
eISSN
1471-2407
Collections
Research Team
Cancer Genomics
Myeloma Group
Myeloma Group